JOHNSON & JOHNSON is 179.5x more valuable than Telix Pharmaceuticals Ltd by market capitalization ($574.10 B vs $3.20 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TLX | JNJ |
|---|---|---|
| Market cap | $3.20 B | $574.10 B |
| US-listed rank | #1752 | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | - | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 95 | 984 |
JOHNSON & JOHNSON is 179.5x more valuable than Telix Pharmaceuticals Ltd by market capitalization ($574.10 B vs $3.20 B).
Full pages: Telix Pharmaceuticals Ltd and JOHNSON & JOHNSON, or browse the full rankings.